T2 Biosystems rises on contract extension for sepsis-detecting diagnostics

T2 Biosystems

28/12/2022 15:24

** Shares of U.S.-based in-vitro diagnostics co T2
Biosystems Inc  TTOO.O  rise 13.2% at $1.2
    ** Co says its contract with Vizient Inc has been extended
through March 31, 2024 
    ** Under the terms of the contract, Vizient will continue to
have access to TTOO's diagnostics systems to detect
sepsis-causing bacterial and fungal pathogens 
    ** Vizient members will continue to have access to broader
exposure and contracted pricing for the T2Dx Instrument, TTOO
adds
    ** Including session's gain, stock down 95.4% YTD
 (Reporting by Pratik Jain in Bengaluru)
 ((Pratik.Jain@thomsonreuters.com;))